Results of histological and OSNA tests in different validation series, histology being the gold standard for comparison
| Reference (first author) | TAB | HIST+/OSNA+ | HIST-/OSNA- | HIST+/OSNA- | HIST-/OSNA+ | All SLN samples | SENS | SPEC | ACC | PPV | NPV | FNR | FRR |
| Tsujimoto 12 | 2 | 43 | 276 | 2 | 2 | 323 | 95.6 | 99.3 | 98.8 | 95.6 | 99.3 | 4.4 | 0.7 |
| Visser24 | 7 | 61 | 267 | 3 | 8 | 339 | 95.3 | 97.1 | 96.8 | 88.4 | 98.9 | 4.7 | 1.1 |
| Schem25 | 13 | 104 | 211 | 0 | 15 | 330 | 100 | 93.4 | 95.5 | 87.4 | 100 | 0 | 0 |
| Tamaki Trial126 | 0 | 19 | 101 | 1 | 3 | 124 | 95 | 97.1 | 96.8 | 86.4 | 99 | 5 | 1 |
| Tamaki Trial226 | 10 | 70 | 348 | 2 | 20 | 440 | 97.2 | 94.6 | 95 | 77.8 | 99.4 | 2.8 | 0.6 |
| Snook18 | 17 | 66 | 313 | 6 | 10 | 395 | 91.7 | 96.9 | 95.9 | 86.8 | 98.1 | 8.3 | 1.9 |
| Feldman27 | 19 | 107 | 868 | 30 | 20 | 1025 | 78.1 | 97.7 | 95.1 | 84.3 | 96.7 | 21.9 | 3.3 |
| Bernet28 | 7 | 33 | 138 | 1 | 2 | 174 | 97.1 | 98.6 | 98.3 | 94.3 | 99.3 | 2.9 | 0.7 |
| Le Frere-Belda14 | 22 | 51 | 413 | 5 | 12 | 481 | 91.1 | 97.2 | 96.5 | 81 | 98.8 | 8.9 | 1.2 |
| All | 97 | 554 | 2935 | 50 | 92 | 3631 | 91.7 | 97 | 96.1 | 85.8 | 98.3 | 8.3 | 1.7 |
Case numbers represent lymph node samples, which is slightly higher than the lymph node number, as larger nodes had to be assayed as multiple samples.
+, positive (including micrometastases/macrometastases for histology and +/++ results for OSNA); −, negative (including isoltaed tumour cells and copy numbers <250/μl of lysate, respectively); ACC, accuracy (concordance rate of the two tests); FNR, false-negative rate (false-negatives/all positives); FRR, false-reassurance rate (false-negatives/all testing negative); HIST, histological; NPV, negative predictive value; OSNA, one-step nucleic acid amplification; PPV, positive predictive value; SENS, sensitivity; SPEC, specificity; TAB, tissue allocation bias (samples excluded from analysis). Values from SENS to FRR are expressed as percentages.